25.05.2012 - With the aim to maintain its status one of the global leading life sciences nations, the UK has set up a large funding initiative.
London – Minister for Universities and Science, David Willetts, announced that £250M has been allocated for the first phase of several five year strategic investment programmes. This includes 26 strategic science programmes and 14 key national research capabilities, to be delivered by eight of the UK's world-leading bioscience research institutes and their university partners. The process will be led by Britain's Biotechnology and Biological Sciences Research Council (BBSRC).
Commenting on the funding, Willetts said: "This investment will sustain excellent science at some of the UK's leading institutes and universities. This will drive growth, support highly skilled jobs and keep the UK at the very forefront of bioscience, with benefits ranging from healthcare to energy and global food security." The plan is thought to help the UK to meet challenges such as sustainably feeding the growing world population, finding alternatives to dwindling fossil fuels and supporting an ageing society to remain healthy for longer.
The Minister made the announcement in a speech during a visit at the Babraham Research Campus. The campus, a BBSRC National Research and Innovation Campus, is one of the privileged institutes and will receive £37M. Others are the Institute of Biological, Environmental and Rural Sciences, Aberystwyth University (£13M), the Genome Analysis Centre in Norwich (£19M), the Roslin Institute at the University of Edinburgh (£23M), the Institute for Animal Health in Pirbright (£38M), the Institute of Food Research in Norwich (£29M), the John Innes Centre in Norwich (£42M) and the Rothamsted Research in Harpenden (£41M).
The initiative complements a funding programme aimed to boost translational medicine, that was announced in April.
03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.
02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.
12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.
METTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications. more